Related Articles
Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first‑line therapy for BRAF‑mutated metastatic melanoma
Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild‑type <em>TP53</em> colon and gastric cancer cells with aberrant KRAS signaling
GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax
MEK inhibitors against MET-amplified non-small cell lung cancer